Siglec-8 binding proteins and uses thereof
AssigneesPhylaxis Bioscience, LLC, Inhibrx, Inc.
InventorsTony Dung-Ling Yao, Andrew M. Eckles, Jacob J. Gano, Bryan Becklund, Brendan P. Eckelman
Life of this patent
Estimating the term…
Abstract
Provided herein are Siglec-8 binding proteins, and methods of using Siglec-8 binding proteins to modulate the biological activity of Siglec-8.
Claims41
An VHH domain that binds Siglec-8, comprising complementarity determining region 1 (CDR1), complementarity determining region 2 (CDR2), and complementarity determining region 3 (CDR3) sequences of a VHH that comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 26, 5, 11, 16, 21, 31, 36, 130-138, 140-148, 161, 163, and 164.
An VHH domain that binds Siglec-8, comprising CDR1, CDR2, and CDR3 sequences set forth in:
- a) SEQ ID NOs:
- 46, 47, and 48, respectively, as defined according to the AbM numbering system;
- b) SEQ ID NOs:
- 149, 150, and 151, respectively, as defined according to the Chothia numbering system;
- c) SEQ ID NOs:
- 152, 153, and 154, respectively, as defined according to the Kabat numbering system;
- d) SEQ ID NOs:
- 155, 156, and 157, respectively, as defined according to the Contact numbering system;
- or
- e) SEQ ID NOs:
- 158, 159, and 160, respectively, as defined according to the IMGT numbering system.
5-8. (canceled)
An VHH domain that binds Siglec-8, comprising CDR1, CDR2, and CDR3 sequences of a VHH that comprises the amino acid sequence of SEQ ID NO:
- 1, 49 or 61.
12-22. (canceled)
26-27. (canceled)
A polypeptide comprising:
- (i) at least two antigen-binding domains that bind Siglec-8 and a multimerization domain;
- or
- (ii) at least three antigen-binding domains that bind Siglec-8.
32-37. (canceled)
(canceled)
41-43. (canceled)
46-47. (canceled)
(canceled)
51-58. (canceled)
(canceled)
67-73. (canceled)
Dependencies are inferred from the claim text.